Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Liposomal Doxorubicin: Effective Treatment For Pediatric Desmoid Fibromatosis

P. Ananth, Annette M Werger, S. Voss, C. Rodríguez-Galindo, K. Janeway
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression‐free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.
This paper references
Aggressive Fibromatosis in Children and Adolescents: The Italian Experience
A. Zaenglein (2011)
Aggressive fibromatosis in children and adolescents
C. Meazza (2010)
Long-term results with radiation therapy for pediatric desmoid tumors.
T. Merchant (2000)
The treatment of desmoid tumors: a stepwise clinical approach.
S. Bonvalot (2012)
Safety and efficacy of highdose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study
SX Skapek (2013)
Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin
G. Wehl (2004)
Hydroxyurea Treatment Can Avoid the Need for Aggressive Surgery in Pediatric Fibromatosis
G. Bisogno (2013)
Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.
S. Salas (2011)
SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
R. Chugh (2010)
Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric Blood & Cancer
P Ananth (2017)
Multimodality treatment of mesenteric desmoid tumours.
M. Bertagnolli (2008)
Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.
S. Skapek (2007)
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).
D. Garbay (2012)
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.
N. Penel (2011)
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
A. Constantinidou (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
Response criteria in oncologic imaging: review of traditional and new criteria.
T. Tirkes (2013)
Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study
S. Skapek (2013)
Desmoid fibromatosis in children and adolescents: a conservative approach to management.
Joshua N. Honeyman (2013)
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
M. Gounder (2011)
Desmoid tumors: A novel approach for local control
C. Baliski (2002)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar